Investors Chronicle - magazine and web content - GSK faces approval delay.
One of GlaxoSmithKline’s blockbuster replacement drugs is having approval problems Richard Hemming
Related Results
GSK faces approval delay.
GSK wins restless leg race
Research and Markets: The Parkinsons Disease Market Is Set To Continue To Gro…
PPSI wins SW Argus press revamp work
Pinguin sauve une usine anglaise de legumes surgeles. (En Manchete Dans Ce Nu…
GlaxoSmithKline (GSK) and SkyePharma announced that the US Food & Drugs Administration (FDA) extended the review period for its ropinerole treatment (Requip XR) for Parkinson’s disease. The FDA’s …
Read the rest of this article with a Free Trial at HighBeam Research.
